Lucentis versus avastin - Is there a light at the end of the tunnel for age-related macular degeneration patients?

Michael Waisbourd, Igal Leibovitch, Anat Loewenstein, Yuval Yassur

Research output: Contribution to journalReview articlepeer-review

Abstract

Age-related macular degeneration is the leading cause of blindness and visual impairment in the developed world. The recently introduced anti-vascular endothelial growth factor (VEGF) intravitreal injections of Ranibizumab (Lucentis) and Bevacizumab (Avastin) generated a heated academic argument: on the one hand Lucentis is the only drug that was proven effective and relatively safe in large prospective double-blinded studies, albeit this drug is expensive and might cost up to $1000 per single injection. On the other hand, Avastin is widely used worldwide as a low cost alternative for Lucentis, with an estimated cost of about $120 per injection, although its efficacy and side effects were investigated only in smaller retrospective studies. The ophthalmic community still lacks definite information regarding which is the preferred drug, and awaits the results of a large prospective study comparing the two drugs.

Original languageEnglish
Pages (from-to)605-606
Number of pages2
JournalHarefuah
Volume147
Issue number7
StatePublished - Jul 2008
Externally publishedYes

Keywords

  • Age-related macular degeneration
  • Avastin
  • Bevacizumab
  • Lucentis
  • Ranibizumab

Fingerprint

Dive into the research topics of 'Lucentis versus avastin - Is there a light at the end of the tunnel for age-related macular degeneration patients?'. Together they form a unique fingerprint.

Cite this